# Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

> **NCT06126003** · — · TERMINATED · sponsor: **BioCorteX Inc** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT06126003
- **Lead sponsor:** BioCorteX Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Did not reach enrollment goals
- **Last updated:** 2024-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126003, "Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06126003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*